Pyrazinamide is a first-line tuberculosis drug with potent sterilizing activity. Variability in drug
exposure may potentially translate into suboptimal treatment responses. This systematic …

Purpose Significant pharmacokinetic variabilities have been reported for isoniazid across
various populations. We aimed to summarize population pharmacokinetic studies of …

Background Dispersible pediatric fixed-dose combination (FDC) tablets delivering higher
doses of first-line antituberculosis drugs in World Health Organization–recommended weight …

Variable pharmacokinetics of rifampin in tuberculosis (TB) treatment can lead to poor
outcomes. Urine spectrophotometry is simpler and more accessible than recommended …

Standard tuberculosis (TB) management has failed to control the growing number of drug-
resistant TB cases worldwide. Therefore, innovative approaches are required to eradicate …

BACKGROUND: Observational real-world studies on therapeutic drug monitoring (TDM) in
relation to pharmacokinetic (PK) target values are lacking. This study aims to describe the …

Introduction Isoniazid (INH) plays an important role in prevention and treatment of
tuberculosis (TB). However, large pharmacokinetic (PK) variations are observed in patients …

Due to interindividual variability in drug metabolism and pharmacokinetics, traditional
isoniazid fixed-dose regimens may lead to suboptimal or toxic isoniazid concentrations in …

Tuberculosis (TB) is an important cause of morbidity and mortality globally. About 3–4% of
hospitalized TB patients require admission to the intensive care unit (ICU); the mortality in …

Purpose Although rifampicin (RIF) is used as a synergistic agent for multidrug-resistant
Acinetobacter baumannii (MDR-AB) infection, the optimal pharmacokinetic (PK) indices of …